Business Model Breakdown
How Rigel Pharmaceuticals Inc Makes Money
RIGL
Market Cap
$479M
Profit Margin
0.0%
Employees
162
The Short Version
Rigel Pharmaceuticals Inc. is a biotechnology company that develops and commercializes innovative medicines, primarily for rare hematologic disorders and cancer. They generate revenue through the sales of their approved drug, TAVALISSE (fostamatinib), which is prescribed for adult patients with chronic immune thrombocytopenia (ITP). The company aims to expand its revenue base significantly through new drug approvals, such as REZLIDHIA for warm autoimmune hemolytic anemia (wAIHA), leveraging its scientific expertise to address unmet medical needs in specialized patient populations.
Where the Revenue Comes From
TAVALISSE sales (currently primary revenue driver)
Potential REZLIDHIA sales (post-approval)
Who buys: Patients suffering from rare hematologic disorders and cancer; healthcare providers and specialists who prescribe these treatments.
Why It Works (Competitive Advantages)
- ✔Proprietary drug (TAVALISSE) for ITP.
- ✔Potential proprietary drug (REZLIDHIA) for wAIHA awaiting approval.
Economic Moat: Narrow (Intangible Assets/IP (patents covering TAVALISSE and REZLIDHIA))
What Our Analysis Says
DVR Score as of April 12, 2026
Rigel Pharmaceuticals (RIGL) remains an extremely high-risk, high-reward investment with a score of 40/100 for 10x growth potential, consistent with the previous analysis. The significant market opportunity for REZLIDHIA (fostamatinib) in warm autoimmune hemolytic anemia (wAIHA) following its prior regulatory submission is a core growth driver. However, the absence of recent financial data (earnings, cash flow, balance sheet) in the provided market intelligence means the company's previously noted 'persistent cash burn and high debt levels' cannot be assessed for improvement, continuing to pose substantial financial risk. The path to achieving 10x growth remains highly speculative, hinging on successful regulatory approval, robust commercialization, and a fundamental shift towards disciplined financial management, none of which are definitively indicated in the current data.